Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
Jeffrey S BergerFrançois LalibertéAkshay KharatDominique LejeuneKenneth Todd MooreYoung JungPatrick LefebvreVeronica AshtonPublished in: Advances in therapy (2021)
These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity and polypharmacy in a commercially-insured US population.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- insulin resistance
- metabolic syndrome
- catheter ablation
- left atrial
- weight loss
- left atrial appendage
- venous thromboembolism
- high fat diet induced
- type diabetes
- heart failure
- weight gain
- percutaneous coronary intervention
- adipose tissue
- adverse drug
- emergency department
- coronary artery disease
- replacement therapy
- pulmonary embolism
- physical activity
- smoking cessation
- acute coronary syndrome
- electronic health record